A Comparative Study on PRO Symptom Monitoring Approaches

By Staff Writer

August 27, 2024

Introduction

Patients with lung cancer often face a grim prognosis, with nearly half being diagnosed at an advanced stage. The 5-year survival rate for lung cancer varies significantly, ranging from 9% to 64% depending on the cancer stage. For years, lung cancer has remained the leading cause of cancer-related deaths. Recent studies, including the SYMPRO-Lung trial, have explored the use of patient-reported outcome (PRO) symptom monitoring to improve health-related quality of life (HRQOL) in these patients.

Understanding PRO Symptom Monitoring

PRO symptom monitoring involves patients reporting their symptoms, which are then used to guide clinical care. The SYMPRO-Lung trial was the first to demonstrate that a patient-initiated (reactive) approach to PRO symptom monitoring was as effective as a physician-initiated (active) response in improving HRQOL 15 weeks after treatment initiation. This was a pragmatic cluster randomised trial. This patient-centred approach could potentially reduce the workload for healthcare practitioners (HCPs) while maintaining clinical efficacy.

Long-Term Effects of PRO Symptom Monitoring

The study extended the observation period to one year to assess the long-term effects of weekly online PRO symptom monitoring. The trial involved 515 lung cancer patients across 14 hospitals. Results indicated that both reactive and active approaches significantly improved long-term HRQOL. Notably, the reactive approach, which involved sending alerts directly to patients, was less labour-intensive for HCPs.

Survival Benefits and Challenges

Previous studies have shown survival benefits with active PRO symptom monitoring. However, these studies often required additional resources, such as funded nursing staff. The SYMPRO-Lung trial did not find significant differences in progression-free survival (PFS) and overall survival (OS) between the intervention and control groups. The lack of statistical significance could be attributed to the study’s limited power and the flexibility given to patients in the reactive group to decide whether to contact their HCPs.

Figure 1. Progression-Free Survival Results of Patient-Initiated (Reactive) vs Physician-Initiated (Active)
Response to Patient-Reported Symptom Monitoring vs Care as Usual (Control)
Figure 2. Overall Survival Results of Patient-Initiated (Reactive) vs Physician-Initiated (Active) Response to
Patient-Reported Symptom Monitoring vs Care as Usual (Control)

Strengths and Limitations

One of the strengths of this study is its pragmatic design, which allowed for the adaptation of the intervention to the specific workflows of each participating hospital. This broad-scale, multicenter approach enhances the generalisability of the findings. However, the study also had limitations, such as differences in patient characteristics between groups and potential selection bias due to the online nature of the intervention. Future research should focus on addressing these limitations and improving algorithm accuracy to minimise false-positive alerts.

Conclusion

The SYMPRO-Lung trial demonstrates that PRO symptom monitoring can improve long-term HRQOL in lung cancer patients. The reactive approach, where patients initiate contact with their HCPs, proved to be as effective as the active approach and less labour-intensive. While no significant survival benefit was observed, the findings justify further research into the implementation of symptom monitoring in routine lung cancer care. Both reactive and active approaches offer flexibility for HCPs and patients, potentially leading to more sustainable and cost-effective care models.

Reference url

Recent Posts

TAVI Cost-Effectiveness in Brazil: Balancing Coverage Expansion and Economic Viability

By Staff Writer

August 21, 2025

The focus on TAVI cost-effectiveness Brazil has gained attention. The country is assessing the expansion of coverage for transcatheter aortic valve implantation (TAVI). This would include patients with severe aortic stenosis who are classified as low surgical risk (STS-PROM <4%) as a first-lin...
Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025
Type 2 diabetes management in adults is undergoing significant changes with the draft 2025 NICE guideline update. What are the main improvements in medication, monitoring, and patient care for adults with type 2 diabetes? The answer: The new NICE recommendations prioritize a broader use of SGL...
FDA Guidance on Overall Survival Assessment in Oncology Trials

By Staff Writer

August 20, 2025

Overall survival assessment serves as the gold standard for determining the true impact of oncology treatments, directly answering patient and provider questions such as: “How will this therapy affect my length of life?” According to the latest FDA guidance, robust overall survival assessment is ...